Argenx Se (ARGXN) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ARGXN Analyst Ratings

Strong Buy

20 Buy

2 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Argenx

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ARGXN Stock 12 Month Forecast

Average Price Target

$18,634.23

▲(16.81% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Argenx Se in the last 3 months. The average price target is $18,634.23 with a high forecast of $23,544.60 and a low forecast of $14,824.37. The average price target represents a 16.81% change from the last price of $15,953.15.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11074":"$11,074","23545":"$23,545","14191.75":"$14,191.8","17309.5":"$17,309.5","20427.25":"$20,427.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":23544.5952015,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18634.229105398997,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":14824.3747565,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$15K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11074,14191.75,17309.5,20427.25,23545],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15953.15,16537.107323192307,17121.064646384613,17705.021969576923,18288.979292769232,18872.93661596154,19456.893939153844,20040.851262346154,20624.808585538463,21208.76590873077,21792.723231923075,22376.680555115385,22960.637878307694,{"y":23544.5952015,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15953.15,16159.386854261462,16365.623708522922,16571.860562784383,16778.097417045847,16984.334271307307,17190.571125568767,17396.807979830228,17603.044834091692,17809.281688353152,18015.518542614613,18221.755396876073,18427.992251137537,{"y":18634.229105398997,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,15953.15,15866.321135115384,15779.492270230769,15692.663405346153,15605.834540461537,15519.005675576922,15432.176810692308,15345.347945807693,15258.519080923077,15171.690216038462,15084.861351153846,14998.03248626923,14911.203621384615,{"y":14824.3747565,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":11075.639,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11385,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11385,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14210,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15022,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15022,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15021.209,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15021.209,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13277.139,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 39,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13000.67,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13000.67,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13000.67,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15953.15,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 76,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$23,545

Average Price Target$18,634

Lowest Price Target$14,824

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Danielle Brill

Truist Financial

$17,963.65

Buy

12.60%

Upside

Reiterated

07/30/26

Analysts Conflicted on These Healthcare Names: Baxter International (NYSE: BAX), Incyte (NASDAQ: INCY) and Argenx Se (NASDAQ: ARGX)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$17,440.44→$18,312.46

Buy

14.79%

Upside

Reiterated

07/28/26

Wedbush Sticks to Its Buy Rating for Argenx Se (ARGX)

Alex Thompson CFA

Stifel Nicolaus

$21,887.75→$22,358.65

Buy

40.15%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Argenx Se (NASDAQ: ARGX)

Yaron Werber

TD Cowen

$19,986.75

Buy

25.28%

Upside

Reiterated

07/28/26

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), NeoGenomics (NEO)

Douglas Tsao

H.C. Wainwright

$16,394.01

Buy

2.76%

Upside

Reiterated

07/28/26

argenx Buy Rating Reaffirmed as FB102 Acquisition and Vyvgart Momentum Support Unchanged $940 Price Target

Gavin Clark-Gartner

Evercore ISI

$17,562.52→$18,469.43

Buy

15.77%

Upside

Reiterated

07/27/26

Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX) and Omeros (NASDAQ: OMER)

Tazeen Ahmad

Bank of America Securities

$19,037.16→$19,097.08

Buy

19.71%

Upside

Reiterated

07/27/26

Argenx Buy Rating Reiterated as Forte Biosciences Deal Broadens Pipeline; $1,088 Price Target Maintained

Matt Phipps

William Blair

―

Buy

―

Reiterated

07/27/26

Analysts Are Bullish on These Healthcare Stocks: Demant (WILLF), Argenx Se (ARGX)

Colleen M. Kusy

Robert W. Baird

$15,120.86→$16,254.49

Hold

1.89%

Upside

Reiterated

07/27/26

Argenx price target raised to $932 from $867 at BairdArgenx price target raised to $932 from $867 at Baird

Thomas Smith

Leerink Partners

$16,655.62→$18,574.07

Buy

16.43%

Upside

Reiterated

07/24/26

Argenx price target raised to $1,065 from $955 at LeerinkArgenx price target raised to $1,065 from $955 at Leerink

Jason Butler

Citizens JMP

$16,463.78→$16,254.49

Buy

1.89%

Upside

Reiterated

07/24/26

Argenx price target lowered to $932 from $944 at CitizensArgenx price target lowered to $932 from $944 at Citizens

Sean Laaman

Morgan Stanley

$20,579.72→$20,928.53

Buy

31.19%

Upside

Assigned

07/24/26

Argenx price target raised to $1,200 from $1,180 at Morgan StanleyArgenx price target raised to $1,200 from $1,180 at Morgan Stanley

Leland Gershell

Oppenheimer

$17,684.61→$18,085.74

Buy

13.37%

Upside

Reiterated

07/24/26

Argenx price target raised to $1,037 from $1,014 at OppenheimerArgenx price target raised to $1,037 from $1,014 at Oppenheimer

Samantha Semenkow

Citi

$20,614.6→$20,980.85

Buy

31.52%

Upside

Reiterated

07/24/26

Argenx price target raised to $1,182 from $1,152 at CitiArgenx price target raised to $1,182 from $1,152 at Citi

James Gordon CFA

Barclays

$15,696.4→$16,568.42

Buy

3.86%

Upside

Reiterated

07/24/26

Argenx price target raised to $950 from $900 at BarclaysArgenx price target raised to $950 from $900 at Barclays

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Danielle Brill

Truist Financial

$17,963.65

Buy

12.60%

Upside

Reiterated

07/30/26

Analysts Conflicted on These Healthcare Names: Baxter International (NYSE: BAX), Incyte (NASDAQ: INCY) and Argenx Se (NASDAQ: ARGX)

Unknown Analyst

Wedbush

Not Ranked

Wedbush

$17,440.44→$18,312.46

Buy

14.79%

Upside

Reiterated

07/28/26

Wedbush Sticks to Its Buy Rating for Argenx Se (ARGX)

Alex Thompson CFA

Stifel Nicolaus

$21,887.75→$22,358.65

Buy

40.15%

Upside

Reiterated

07/28/26

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (NASDAQ: SMMT) and Argenx Se (NASDAQ: ARGX)

Yaron Werber

TD Cowen

$19,986.75

Buy

25.28%

Upside

Reiterated

07/28/26

Analysts Are Bullish on Top Healthcare Stocks: Argenx Se (ARGX), NeoGenomics (NEO)

Douglas Tsao

H.C. Wainwright

$16,394.01

Buy

2.76%

Upside

Reiterated

07/28/26

argenx Buy Rating Reaffirmed as FB102 Acquisition and Vyvgart Momentum Support Unchanged $940 Price Target

Gavin Clark-Gartner

Evercore ISI

$17,562.52→$18,469.43

Buy

15.77%

Upside

Reiterated

07/27/26

Analysts Offer Insights on Healthcare Companies: Argenx Se (NASDAQ: ARGX) and Omeros (NASDAQ: OMER)

Tazeen Ahmad

Bank of America Securities

$19,037.16→$19,097.08

Buy

19.71%

Upside

Reiterated

07/27/26

Argenx Buy Rating Reiterated as Forte Biosciences Deal Broadens Pipeline; $1,088 Price Target Maintained

Matt Phipps

William Blair

―

Buy

―

Reiterated

07/27/26

Analysts Are Bullish on These Healthcare Stocks: Demant (WILLF), Argenx Se (ARGX)

Colleen M. Kusy

Robert W. Baird

$15,120.86→$16,254.49

Hold

1.89%

Upside

Reiterated

07/27/26

Argenx price target raised to $932 from $867 at BairdArgenx price target raised to $932 from $867 at Baird

Thomas Smith

Leerink Partners

$16,655.62→$18,574.07

Buy

16.43%

Upside

Reiterated

07/24/26

Argenx price target raised to $1,065 from $955 at LeerinkArgenx price target raised to $1,065 from $955 at Leerink

Jason Butler

Citizens JMP

$16,463.78→$16,254.49

Buy

1.89%

Upside

Reiterated

07/24/26

Argenx price target lowered to $932 from $944 at CitizensArgenx price target lowered to $932 from $944 at Citizens

Sean Laaman

Morgan Stanley

$20,579.72→$20,928.53

Buy

31.19%

Upside

Assigned

07/24/26

Argenx price target raised to $1,200 from $1,180 at Morgan StanleyArgenx price target raised to $1,200 from $1,180 at Morgan Stanley

Leland Gershell

Oppenheimer

$17,684.61→$18,085.74

Buy

13.37%

Upside

Reiterated

07/24/26

Argenx price target raised to $1,037 from $1,014 at OppenheimerArgenx price target raised to $1,037 from $1,014 at Oppenheimer

Samantha Semenkow

Citi

$20,614.6→$20,980.85

Buy

31.52%

Upside

Reiterated

07/24/26

Argenx price target raised to $1,182 from $1,152 at CitiArgenx price target raised to $1,182 from $1,152 at Citi

James Gordon CFA

Barclays

$15,696.4→$16,568.42

Buy

3.86%

Upside

Reiterated

07/24/26

Argenx price target raised to $950 from $900 at BarclaysArgenx price target raised to $950 from $900 at Barclays

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

MLYSMineralys Therapeutics, Inc.

AMLXAmylyx Pharmaceuticals Inc

ZURAZura Bio

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Argenx Se

3 Months

Yatin SunejaGuggenheim

Success Rate

17/21 ratings generated profit

Average Return

+6.64%

Copying Yatin Suneja's trades and holding each position for 3 Months would result in 80.95% of your transactions generating a profit, with an average return of +6.64% per trade.

1 Year

Allison BratzelPiper Sandler

Success Rate

26/27 ratings generated profit

Average Return

+29.31%

Copying Allison Bratzel's trades and holding each position for 1 Year would result in 96.30% of your transactions generating a profit, with an average return of +29.31% per trade.

2 Years

Akash TewariJefferies

Success Rate

29/29 ratings generated profit

Average Return

+65.66%

Copying Akash Tewari's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +65.66% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ARGXN Analyst Recommendation Trends

Rating

Mar 26

Apr 26

May 26

Jun 26

Jul 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ARGXN has received 76 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. ARGXN average Analyst price target in the past 3 months is 18,634.23.

Each month's total comprises the sum of three months' worth of ratings.

ARGXN Financial Forecast

ARGXN Earnings Forecast

Next quarter’s earnings estimate for ARGXN is $131.51 with a range of $110.68 to $164.28. The previous quarter’s EPS was $126.98. ARGXN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.81% of the time in the same period. In the last calendar year ARGXN has Performed in-line its overall industry.

ARGXN Sales Forecast

Next quarter’s sales forecast for ARGXN is $28.50B with a range of $26.29B to $29.78B. The previous quarter’s sales results were $48.85B. ARGXN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.23% of the time in the same period. In the last calendar year ARGXN has Performed in-line its overall industry.

ARGXN Stock Forecast FAQ

What is MX:ARGXN’s average 12-month price target, according to analysts?

Based on analyst ratings, Argenx Se’s 12-month average price target is 18,634.23.

What is MX:ARGXN’s upside potential, based on the analysts’ average price target?

Argenx Se has 16.81% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Argenx Se a Buy, Sell or Hold?

Argenx Se has a consensus rating of Strong Buy, which is based on 20 buy ratings, 2 hold ratings and 0 sell ratings.

What is Argenx Se’s share price target?

The average share price target for Argenx Se is 18,634.23. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $23,544.60 ,and the lowest forecast is $14,824.37. The average share price target represents 16.81% Increase from the current price of $15,953.15.

What do analysts say about Argenx Se?

Argenx Se’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of Argenx Se?

To buy shares of MX:ARGXN, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Argenx Se (ARGXN) Stock Forecast & Price Target

ARGXN Analyst Ratings

ARGXN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Argenx Se

ARGXN Analyst Recommendation Trends

ARGXN Financial Forecast

ARGXN Earnings Forecast

ARGXN Sales Forecast

ARGXN Stock Forecast FAQ

Detailed List of Analyst Forecasts